Biotechnology firm Amgen (Nasdaq: AMGN) reported first-quarter earnings that increased from last year and exceeded estimates, while revenues remained unchanged. Meanwhile, the management
Categories
Biotechnology
Fennec Pharma stock plunges to all-time low
Fennec Pharmaceuticals Inc. (FENC) stock plunged to an all-time low of $4.69 on Tuesday. Investors were concerned about the future of the
Aldeyra Therapeutics stock resumes trading, surges about 60% on positive trial results
After getting halted in Nasdaq for sometime, shares of Aldeyra Therapeutics (ALDX) resumed trading and climbed up about 60% during the pre-market
Cesca Therapeutics reports wider net loss for FY18 as sales fall
Cesca Therapeutics (KOOL) Monday reported a wider net loss for fiscal 2018 when revenues of the biotechnology firm declined sharply. The company’s
Cara Therapeutics stock surges after reporting Q4 earnings results
Cara Therapuetics (CARA) reports a loss of $20.7 million or $0.52 per share on revenue of $5.5 million for the fourth quarter
Earnings Preview Q4: Cara Therapeutics’ success in 2019 will depend on Korsuva trial outcomes
Cara Therapeutics (CARA) is scheduled to report its fourth quarter and full-year 2018 financial results on Tuesday, March 12, after the regular
Exelixis tops bottom and topline targets for Q4, stock rises
Exelixis (EXEL) reported Q4 earnings of 37 cents per share and revenue of $228.6 million that beat analysts' views. Analysts had expected
Four cheap biotech stocks to buy
In the current environment, investment in the biotech stocks could be a risky recommendation for the investors. Despite its erratic behavior, the
Earnings: Array BioPharma delivers strong Q2 results, investors cheer
Array BioPharma (ARRY) reported 44% jump in second-quarter revenue to $82.5 million, driven by higher product sales and recognition of $40 million
Earnings preview: HIV to drive topline growth for Gilead Sciences in Q4
Biotechnology company Gilead Sciences (GILD) is scheduled to report fourth-quarter earnings results after the closing bell on Monday, February 4. The company
Amgen set to report Q4 earnings on Jan. 29. What’s in store?
Amgen (AMGN) will be reporting its fourth quarter and full-year 2018 earnings results on Tuesday, January 29 after market closes. Analysts expect
Cambrex Corp. completes acquisition of Avista Pharma solutions
Life sciences company Cambrex Corp. (CBM) Wednesday completed its previously announced acquisition of Avista Pharma Solutions, a biotech firm engaged in the
Avid Bioservices Q2 loss narrows despite lower revenues; reaffirms outlook
Avid Bioservices (CDMO) reported a narrower net loss for the second quarter of 2019, helped by a sharp decline in costs. Revenues,
Earnings Preview: Q2 results may set the tone for Avid Bioservices’ recovery
Avid Bioservices (CDMO), a contract manufacturer in the biotechnology industry, is scheduled to release its second-quarter financial results Monday after the closing